56461-20-2

Basic information

• Product Name: 1-OXO-INDAN-4-CARBOXYLIC ACID
• Synonyms: 1-INDANONE-4-CARBOXYLIC ACID;1-OXO-INDAN-4-CARBOXYLIC ACID;1-oxo-2,3-dihydro-1H-indene-4-carboxylic acid;1H-Indene-4-carboxylic acid, 2,3-dihydro-1-oxo-;1-oxo-2,3-dihydroindene-4-carboxylic acid
• CAS NO: 56461-20-2
• Molecular Formula: C₁₀H₈O₃
• Molecular Weight: 176.17
• Product Categories: Benzocycles;pharmacetical
• Mol File: 56461-20-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 225-226 °C
• Boiling Point: 380.4±31.0 °C(Predicted)
• Appearance: /
• Density: 1.381±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.69±0.20(Predicted)
• CAS DataBase Reference: 1-OXO-INDAN-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-OXO-INDAN-4-CARBOXYLIC ACID(56461-20-2)
• EPA Substance Registry System: 1-OXO-INDAN-4-CARBOXYLIC ACID(56461-20-2)

Safety Data

• Hazardous Substances Data: 56461-20-2(Hazardous Substances Data)

Usage

Description

1-Oxo-indan-4-carboxylic acid, also known as 1-Indanone-4-carboxylic Acid, is an organic compound with the molecular formula C9H7O3. It is a key intermediate in the synthesis of various pharmaceutical compounds and has been identified for its potential applications in the development of novel drugs.

Uses

Used in Pharmaceutical Industry:
1-Oxo-indan-4-carboxylic acid is used as a reactant for the preparation of dihydroindenopyrazoles, which are multitargeted receptor tyrosine kinase inhibitors. These inhibitors play a crucial role in the development of targeted therapies for various diseases, including cancer, by blocking the activity of specific enzymes involved in cell signaling pathways.

InChI:InChI=1S/C10H8O3/c11-9-5-4-6-7(9)2-1-3-8(6)10(12)13/h1-3H,4-5H2,(H,12,13)

Upstream product

• 612-40-8 2-carboxycinnamic acid 
• 447-53-0 1,2-Dihydronaphthalene 
• 91-20-3 naphthalene 
• 612-17-9 1,4-dihydronaphthalene 
• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 
• 776-79-4 2-(2-carboxyethyl)benzoic acid 

Downstream Products

• 68569-87-9 4-p-Aethylbenzoyl-1-indanon 
• 56461-75-7 4-(3'-Methyl-4'-chlor-benzoyl)-1-indanon 
• 55934-10-6 methyl 1-oxo-2,3-dihydro-1H-indene-4-carboxylate 
• 1213591-14-0 1-amino-2,3-dihydro-1H-indene-4-carbonitrile 
• 1213099-69-4 (S)-(1-amino-2,3-dihydro-1H-indene-1-yl)-4-carbonitrile 
• 56461-09-7 4-(p-toluoyl)indan-1-one 
• 56461-16-6 4-(p-chlorobenzoyl)indan-1-one 
• 68569-94-8 4-(2,4,6-Trimethyl-benzoyl)-1-indancarbonsaeure 
• 56461-39-3 4-p-t-Butylbenzoyl-1-indancarbonsaeure 
• 56461-47-3 4-(2,4,6-Trimethylbenzoyl)-1-indancarboxamid 
• 56461-38-2 4-(3'-Methyl-4'-chlor-benzoyl)-1-indancarbonsaeure 
• 56461-51-9 1-cyano-4-(p-t-butylbenzoyl)indan 
• 56461-56-4 4-(2',4',6'-Trimethylbenzoyl)-1-indanoncarbonitril 
• 56461-37-1 4-p-Brombenzoyl-1-indancarbonsaeure 

Relevant articles and documents

Synthesis, biological evaluation and molecular docking studies of indeno [1, 2-c] pyrazol derivatives as inhibitors of mitochondrial malate dehydrogenase 2 (MDH2)

Hypoxia inducible factor-1 (HIF-1) is a pivotal transcription factor, which is strongly correlated with the induction of angiogenesis, tumor survival, metastasis, and cell proliferation, making it a pivotal therapeutic target for solid tumor therapeutic agents. Herein, a new series of multi-functional chemical probes were designed including principal groups, viz. adamantyl and indene, at various locations of the parent compound LW6. Molecular docking studies were performed on the designed compounds and their relationship with HIF-1α and malate dehydrogenase 2 (MDH2). Inhibition of MDH2 by our compounds was expected to decrease the NADH level. Indeed, treatment of the breast cancer cell line 4T1 led to a strong reduction of the NADH concentration. The greatest reduction in NADH production in mitochondria was observed with (E)-3-(4-((3r, 5r, 7r)-adamantan-1-yl) phenoxy)-N-(5-(piperidine-1-carbonyl)-1, 4-dihydroindeno [1, 2-c] pyrazol-3-yl) acrylamide (18: IC50 = 59 nM), and has the best inhibitory potential under hypoxic conditions (MCF-7: IC50 = 57 nM). This compound also gave one of the highest docking “higher than the score obtained with LW6 in parallel (?31.63 kcal/mol) in the initial docking runs (PDB Code: 4WLO). Other related compounds with good yields were also synthesized from docking results, and all the synthesized compounds (14, 18, 22, 26, 29, 30) were evaluated in vitro on human adenocarcinoma cell lines.

SUBSTITUTED BICYCLIC COMPOUNDS AS INHIBITORS OF EZH2

The present invention provides compounds of formula 1, isotopic forms, stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, solvates, N-oxides, S-oxides and polymorphs thereof, and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders mediated by EZH2 (enhancer of zeste homolog 2), particularly cancer.

TRICYCLIC PYRAZOLE KINASE INHIBITORS

Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.